Difference between revisions of "Part:BBa K2976006"
(→‎MIT MAHE 2020)
 
Line 26: Line 26:
  
  
−
==MIT MAHE 2020==
+
==MIT_MAHE 2020==
 
'''Summary'''
 
'''Summary'''
  

Latest revision as of 18:29, 23 October 2020


Anti-PD-L1 peptide

Usage and Biology

Anti-PD-L1 peptide selectively binds to programmed death ligand 1 (PD-L1), an immune checkpoint protein that is overexpressed in many cancer cell lines. Recent study has demonstrated that the Mtb-infected macrophages express more PD-L1 than normal ones. Thus, PD-L1 could be a promising target for intracellular Mtb therapy. In 2019 CPU_CHINA project, anti-PD-L1 peptide is displayed on the surface of the exosome to specifically targeting the Mtb-infected macrophages.


Characteristics

Anti-PD-L1 peptide was designed as a fusion protein with lamp2 and HA tag. With the confirmation of HA tag (Fig.1), the expression of anti-PD-L1 was confirmed as well.

Figure 1: Western blot result of exosome protein.

For more details, please check out our demonstrate page.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]



MIT_MAHE 2020

Summary

Anti-PD-L1 peptide selectively binds to programmed death ligand 1 (PD-L1), an immune checkpoint protein that is overexpressed in many cancer cell lines. Recent study has demonstrated that the Mtb-infected macrophages express more PD-L1 than normal ones. Thus, PD-L1 could be a promising target for intracellular Mtb therapy.

References

1. Liu, H., Zhao, Z., Zhang, L. et al. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. j. immunotherapy cancer 7, 270 (2019). https://doi.org/10.1186/s40425-019-0705-y